Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE AND ACETIC ACID versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE AND ACETIC ACID versus KENALOG.
HYDROCORTISONE AND ACETIC ACID vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to increased lipocortin synthesis, inhibition of phospholipase A2, decreased arachidonic acid release, and reduced prostaglandin and leukotriene production; it also suppresses cytokine expression and immune cell migration. Acetic acid is a weak acid that lowers local pH, inhibiting bacterial and fungal growth and disrupting microbial cell membranes.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
Instill 5 drops into affected ear(s) twice daily for 7-10 days; or as directed by physician.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Plasma t1/2: 1.5-2 hours; biological t1/2: 8-12 hours (based on HPA axis suppression).
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Renal: ~60-70% as metabolites; biliary/fecal: ~10-15%; unchanged drug: <5%.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category D/X
Category C
Corticosteroid
Corticosteroid